Medication Monitor

Generic Name (Trade Name—Company)
April 1, 2011


New 40 mg/mL suspension


Adjunctive treatment of seizures associated with Lennox-Gastaut syndrome in patients 4 years of age and older

A 40 mg/mL oral suspension of rufinamide has been approved by FDA. This suspension is equivalent to the already available 200 mg and 400 mg rufinamide tablets on a mg-per-mg basis. The suspension should be dosed with the supplied calibrated oral dosing syringe and adapter. Key counseling points for patients using this new formulation include shaking the medication before each use, replacing the cap securely after opening, keeping the suspension in an upright position at room temperature, and using the product within 90 days of first opening the bottle.